Andere Kunden interessierten sich auch für
![Biosensors and Invasive Monitoring in Clinical Applications]( "Biosensors and Invasive Monitoring in Clinical Applications")
Biosensors and Invasive Monitoring in Clinical Applications37,99 €![Infiltrating Lobular Carcinoma of the Breast]( "Infiltrating Lobular Carcinoma of the Breast")
Infiltrating Lobular Carcinoma of the Breast44,99 €![Endometrioid carcinomas of the endometrium]( "Endometrioid carcinomas of the endometrium")
Endometrioid carcinomas of the endometrium29,99 €![Retinal disorders of vascular origin]( "Retinal disorders of vascular origin")
Retinal disorders of vascular origin39,99 €![Invasive pulmonary aspergillosis in children]( "Invasive pulmonary aspergillosis in children")
Invasive pulmonary aspergillosis in children36,99 €![Chronic hepatitis B: Non-invasive markers predictive of fibrosis]( "Chronic hepatitis B: Non-invasive markers predictive of fibrosis")
Chronic hepatitis B: Non-invasive markers predictive of fibrosis39,99 €![Non-invasive ventilation in the emergency room]( "Non-invasive ventilation in the emergency room")
Non-invasive ventilation in the emergency room36,99 €
Invasive lobular carcinoma (ILC) is the second most common type of invasive breast cancer after nonspecific invasive carcinoma (NSCLC). Its frequency is estimated to be between 1 and 15% of invasive breast tumors. It is a particular clinico-pathological entity, characterized by a difficult clinical and radiological diagnosis. The diagnosis is anatomopathological. It is often associated with lobular carcinoma in situ (LCIS). The latter is part of non-invasive lobular neoplasia (NLNI) which is a lesional spectrum of atypical epithelial proliferation originating at the ductulo-lobular end unit. The latest 2019 WHO classification of breast tumors recognizes a new subtype of CLIS which is CLIS florid.